Hematology/oncology clinics of North America.Hematol Oncol Clin North Am.2017 Feb;31(1):83-99. doi: 10.1016/j.hoc.2016.08.003.
Activating mutations in the epidermal growth factor receptor (EGFR) are present in approximately 15% of US patients with lung adenocarcinoma. EGFR tyrosine kinase inhibitors are associated with high response rate and progression-free survival for patients with non-small cell lung cancer with this ge
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.
Durm G1, Hanna N2.
Hematology/oncology clinics of North America.Hematol Oncol Clin North Am.2017 Feb;31(1):71-81. doi: 10.1016/j.hoc.2016.08.002.
The landscape for the second- and third-line treatment of advanced non-small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following progression on platinum-based first-line chemotherapy. However, there remains a role for
Int J Hematol 73, 222-225. 2. Yamamoto K, Nakamura Y, Arai H, Aoyagi M, Saito K, Furusawa S, Mitani K. (2001): Translocation (14;19)(q32;q13) detected by spectral karyotyping and lack of BCL3 rearrangement in CD5-positive ...
myeloid leukemia cell line with trisomy 18 established from overt leukemia after myelodysplastic syndrome. Int. J. Hematol. 67: 153-164, 1998. 12. Yamamoto, K., Hamaguchi, H., Nagata, K., and Taniwaki, M.: A variant Burkitt-type ...